Weishen Pharmaceutical Technology (Shanghai) Co., Ltd.

Primary objective: To evaluate the safety and tolerability of VD1219 after single and multiple oral administration in healthy adult subjects in China and in Chinese patients with chronic hepatitis B. Secondary objectives: 1) To evaluate the pharmacokinetic (PK) characteristics of VD1219 and its major metabolites (if applicable) after single and multiple oral administration in healthy adult subjects; 2) To evaluate the pharmacokinetic (PK) characteristics of VD1219 after administration in Chinese patients with chronic hepatitis B; 3) To evaluate the preliminary efficacy of VD1219 after administration in Chinese patients with chronic hepatitis B.